Opdivo® (Nivolumab) Intravenous Infusion Approved for Supplemental Indication of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck with Disease Progression on or after Platinum-based Therapy in Taiwan  2017.08.16

By JPN, Pharmaceutical

 

Opdivo® (Nivolumab) Intravenous Infusion Approved for Supplemental Indication of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck with Disease Progression on or after Platinum-based Therapy in Taiwan

http://www.ono.co.jp/eng/news/pdf/sm_cn170816_1.pdf

More from tokioX :

  1. FDA ：Opdivo® as the First New Medication for Certain Patients with Previously Treated Small Cell Lung Cancer
  2. 💊Ono Enters into Exclusive License Agreement with Karyopharm to Develop and Commercialize Selinexor and KPT-8602, XPO1 Inhibitors  20171012
  3. 👾Opdivo® (Nivolumab) Intravenous Infusion Approved for Expanded Use in Advanced Non-squamous Non-small Cell Lung Cancer which Has Been Previously Treated with Platinum-based Therapy in Taiwan News Release
  4. Opdivo® (Nivolumab) Intravenous Infusion Approved for Expanded Use in Unresectable or Metastatic Melanoma in South Korea  20170919
  5. Two important clinical trials of Ono Pharmaceuticals, Opivo® (generic name: niborumab) demonstrate the benefits of three-year survival in patients   20170911
  6. Ochanomizu University Researchers Solve Velocity Jump Mystery in Tire Rubber .  2017/09/05
  7. Opdivo® (Nivolumab) Intravenous Infusion Approved for Supplemental Indications of Advanced Renal Cell Carcinoma, Relapsed or Progressed Classical Hodgkin Lymphoma, Recurrent or Metastatic Head and Neck, Locally Advanced or Metastatic Urothelial Carcinoma, and Unresectable or Metastatic Melanoma in Combination with Ipilimumab in South Korea News Release  20170830